All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Clinical and pathologic correlates between feline and human hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC) and restrictive cardiomyopathy (RCM) have been previously identified \[[@pone.0194342.ref001]--[@pone.0194342.ref004]\]. As a result, these feline cardiomyopathies are believed to represent naturally occurring animal models of the equivalent human conditions. The influence of a number of systemic diseases on the human myocardium have been thoroughly documented but such changes are less well characterised in cats, other than the hypertrophic effect of hyperthyroidism \[[@pone.0194342.ref005]--[@pone.0194342.ref014]\].

Hypersomatotropism (HS), resulting from a functional pituitary adenoma or hyperplasia of the *pars distalis* of the anterior pituitary gland, causes a syndrome of growth hormone (GH) excess: in skeletally mature patients, this results in the disease known as acromegaly. In humans with HS, cardiovascular disease is a significant contributor to morbidity and mortality \[[@pone.0194342.ref015]--[@pone.0194342.ref017]\] with approximately 60% of patients suffering a cardiovascular cause of death \[[@pone.0194342.ref018]\]. Even without clinical evidence of heart failure, increases in left ventricular (LV) mass and echocardiographic measures of LV wall thickness are observed, in addition to impaired overall cardiac performance and a high prevalence of valve disease \[[@pone.0194342.ref019]--[@pone.0194342.ref023]\]. Furthermore, higher IGF-1 and GH concentrations are significantly associated with worse cardiac dysfunction and increased LV mass, independent of impaired glucose tolerance and systemic hypertension \[[@pone.0194342.ref024]\]. Histopathology typically detects myocardial fibrosis and myocyte hypertrophy, with some samples demonstrating cellular infiltrates or small vessel disease in addition \[[@pone.0194342.ref025]\].

Like humans, cats may develop HS in middle to old age and similar to humans, the disease is thought to be increasing in prevalence. Recent work indicates that 25--33% of diabetic cats have HS \[[@pone.0194342.ref026], [@pone.0194342.ref027]\] which suggests that the disease is significantly more common in cats than in humans. Cats with HS most frequently present with signs consistent with of diabetes mellitus (DM) \[[@pone.0194342.ref026]--[@pone.0194342.ref031]\] although case reports of non-diabetic acromegalic cats also exist \[[@pone.0194342.ref032], [@pone.0194342.ref033]\].

Recently, a study evaluating environmental toxin levels in plasma of cats with acromegaly has suggested a link between organohalogenated contaminants and the etiology of acromegaly, which has led to similar studies in human acromegalics \[[@pone.0194342.ref034]\].

Although the physical manifestations of acromegaly on tissue growth can be subtle in the early phases of the disease, they have been well characterised in cats \[[@pone.0194342.ref027], [@pone.0194342.ref028], [@pone.0194342.ref035], [@pone.0194342.ref036]\]. However, the cardiovascular effects of feline HS are less well described. To date, only two case series have been published reporting a high prevalence of cardiac disease and heart failure in acromegalic cats \[[@pone.0194342.ref028], [@pone.0194342.ref037]\]; however, the value of these reports is limited by small numbers and a lack of control groups with which to draw comparisons. An additional confounding factor in feline studies is the high prevalence of hypertrophic cardiomyopathy (HCM) estimated at approximately 15%, with a higher prevalence in aged individuals \[[@pone.0194342.ref038]--[@pone.0194342.ref040]\]. It is possible that a large proportion of the echocardiographic and histopathological findings previously reported in feline HS actually reflected primary incidental HCM (defined as a single diastolic measurement of left ventricular wall thickness ≥6mm) rather than myocardial changes directly caused by acromegaly. A further complication is the potential confounding effect of diabetes on the feline myocardium. Although diabetes causes LV hypertrophy in humans \[[@pone.0194342.ref041],[@pone.0194342.ref042]\], the cardiovascular effect of diabetes in cats is poorly understood. One retrospective case series did report a greater prevalence of cardiac disease in diabetic cats than age-matched controls \[[@pone.0194342.ref043]\], whilst another study evaluating serial echocardiographic changes in cats with DM suggested that diastolic dysfunction was associated with the diabetic state \[[@pone.0194342.ref044]\]. No studies investigating the potential pro-hypertrophic effect of DM in cats have been published.

The objective of this study was to describe a specific cardiomyopathy in cats associated with spontaneously occurring HS, whilst accounting for potential confounding factors such as HCM and diabetic cardiomyopathy, and to explore how closely this mirrors the syndrome recognised in humans.

Methods {#sec006}
=======

Patient selection {#sec007}
-----------------

This study did not involve the use of experimental animals. Ethical approval was granted by the Royal Veterinary College Ethical Review Board (*URN 2011 1120; URN 2017 1734--2*) and written owner consent for study participation was obtained. Healthy cats (controls) were recruited through a geriatric cat clinic organised in two veterinary general practices. Data on cats with diabetes mellitus but without acromegaly (DM group) and those with DM and HS (HS group) were prospectively collected between October 2009 and October 2016 at a veterinary teaching hospital. Inclusion criteria for the HS group were plasma IGF-1 \>1000ng/ml and a contrast enhancing pituitary enlargement detectable on computed tomography (CT) imaging (pituitary height \> 4.0mm; [Fig 1](#pone.0194342.g001){ref-type="fig"}) \[[@pone.0194342.ref026]\]. All HS cats were diabetic at the time of enrolment. Inclusion criteria for the DM group were clinical signs and clinicopathologic findings consistent with DM and a circulating IGF-1 concentration \<800 ng/ml \[[@pone.0194342.ref029]\]. Diabetic cats with equivocal results for the diagnosis of HS (IGF-1 \>800ng/ml but \<1000 ng/ml, or \>1000 ng/ml with CT imaging not performed or yielding equivocal findings) were excluded from the study. Inclusion criteria for the healthy control group were no evidence of systemic disease on physical examination and routine haematology and biochemistry analysis, no glycosuria on urinalysis and a circulating IGF-1 concentration \<800ng/ml.

![Composite image to demonstrate a pituitary mass typical of cats with acromegaly.\
Transverse (left) and saggital (middle) CT images showing a contrast enhancing pituitary mass (\>4mm height) in a cat with acromegaly. Without treatment, the cat was euthanised some months later and post-mortem examination demonstrated the large pituitary mass (right). Histopathology was consistent with an acidophil adenoma.](pone.0194342.g001){#pone.0194342.g001}

Exclusion criteria applicable to all groups were: previous diagnosis or treatment for cardiac disease, diagnosis of hyperthyroidism or other concurrent endocrinopathies, or inappropriate temperament for echocardiography or venepuncture. Cats with previously diagnosed systemic hypertension were also excluded, but cats presenting to the clinic with a measurement of high systolic blood pressure (\>170mmHg) were still included if fundoscopy did not detect changes consistent with hypertensive retinopathy \[[@pone.0194342.ref045]\].

Clinical procedures {#sec008}
-------------------

All cats underwent systolic blood pressure measurement (Doppler technique)(45), echocardiography and venepuncture. Blood sampling was performed for clinical purposes and samples were taken before insulin administration and following 8--10 hours of food withdrawal. Residual serum and ethylenediaminetetraacetic acid (EDTA) plasma were separated into aliquots and stored at -80C within 30 minutes of collection.

Cats that were treated for HS had serial echocardiography and blood sampling performed. Treatment decisions were based upon owner choice and clinician advice at the time of diagnosis and alterations to insulin therapy were made according to individual requirements by or under the supervision of a Board certified veterinary Internist (SN). Options for treatment were medical, using long-acting once monthly somatostatin analogue pasireotide (SOM230; Signifor™, Novartis, Basel, Switzerland) injections (8 mg/kg) \[[@pone.0194342.ref046]\], or surgical through trans-sphenoidal hypophysectomy \[[@pone.0194342.ref047]\].

Echocardiography was performed by or under the supervision of a Board certified veterinary cardiologist, using standardised equipment (Vivid 7 ultrasound machine, 7s probe; GE Systems, Hatfield, Hertfordshire, UK) and protocol \[[@pone.0194342.ref001]--[@pone.0194342.ref004]\]. Studies were recorded from conscious, unsedated animals using a 7.5mHz phased array transducer. Measurements were an average of 3 consecutive cardiac cycles and were performed offline by a single operator (KB), blinded to patient group and timing of echocardiography. Data were entered into an electronic database, along with patient details (age, sex, breed, neuter status and study group).

Circulating concentrations of IGF-1, frustosamine and total T4 were measured from blood samples. Residual samples were stored and batch analysis of cardiac biomarkers (NTproBNP and cardiac troponin I) was performed after completion of the study by a commercial reference laboratory (IDEXX Laboratories Ltd, Wetherby, Yorkshire, UK).

Histopathological investigation {#sec009}
-------------------------------

For the purpose histopathological investigations, records of the Royal Veterinary College Anatomic Pathology Service tissue archive were searched for the following:

1.  Geriatric cats (control group) without previously diagnosed heart disease and no clinical or necropsy evidence of DM or HS.

2.  Cats with confirmed HCM which was associated with clinical signs of congestive heart failure or suspected sudden cardiac death (SCD) \[[@pone.0194342.ref048]\].

3.  Cats with confirmed HS, irrespective of history of cardiac clinical signs.

Age-matching of cats in the HCM, control and HS groups was attempted. The possible inclusion of cats with occult HCM in the control group was an intentional aim to make the group more representative of a population of cats where HCM is commonplace in middle to old-age \[[@pone.0194342.ref040]\]. This allowed for more appropriate between-group comparisons, since it recognises the possibility that cats in the HS group may have had concurrent, primary HCM in addition to any potential secondary changes induced by their systemic endocrine disease.

A histopathological diagnosis of HS was made if acidophil hyperplasia, adenoma or adenocarcinoma of the *pars distalis* of the anterior pituitary at necropsy was confirmed by a Board-certified pathologist or a Resident under direct supervision. All reports were reviewed by a single Board-certified pathologist (NH), who also repeated the histopathological exam on any stored pituitary tissue which was available for review. In this study, hyperplastic lesions were characterised as multiple non-encapsulated well-demarcated small proliferations of acidophils that do not compress adjacent parenchyma. Acidophil adenomas were focal well-demarcated, expansile masses replacing and compressing normal parenchyma occasionally bordered by a thin partial to complete fibrous capsule \[[@pone.0194342.ref049]\]. Cases with concurrent disease processes which could contribute to LVH (evidence of adenomatous thyroid hyperplasia or thyroid carcinoma) \[[@pone.0194342.ref009], [@pone.0194342.ref050]\], and evidence of end-organ damage characteristic of systemic hypertension \[[@pone.0194342.ref051]\] were excluded. Clinical records were manually reviewed by a single operator (LW) for age, breed, sex, history of DM, IGF-1 concentration, echocardiographic findings (if present), treatment provided, and cause of death if known.

Gross pathology reports were reviewed for body weight (kg), heart weight (g) and thickness (mm) of the right ventricular free wall (RVFW), interventricular septum (IVS) and left ventricular free wall (LVFW) on a transverse cross section (perpendicular to the long axis of the ventricles) a third of distance from apex to base from epicardium to endocardium, excluding papillary muscles, as a single measurement using a millimetre rule; as previously described in cats \[[@pone.0194342.ref048]\]. The expected ratio of RVFW: IVS: LVFW is 1:3:3 and the reference range for relative heart weight used was 0.28--0.88% of body weight \[[@pone.0194342.ref052]\].

Cardiac histopathology slides of sections from cardiac tissue preserved in 4% neutral buffered formalin and routinely embedded in paraffin blocks were stained with hematoxylin-eosin and Masson trichrome. Slides were reviewed by a single feline cardiac pathologist (LW) in a blinded manner. Using a high-definition microscope (Olympus BX51TF, Olympus, Southend-on-Sea, UK), section(s) of myocardium on each slide were initially scanned at low power (x10 and x20 magnifications). Representative areas were subsequently examined systematically at x40 and x100 magnification, respectively.

Myocyte hypertrophy, myofiber disarray, interstitial, perivascular and replacement fibrosis and small intramural artery pathology were scored in a representative section, which was a transverse section to include LVFW and IVS wherever available, at x40 magnification as previously described \[[@pone.0194342.ref048]\]. In the absence of a published reference interval for feline myocyte size, scoring of hypertrophy was semiquantitative, and no quantitative analysis of myocyte size was made. Myocyte hypertrophy was defined as large myocytes with large, rectangular, hyper-chromic nuclei and graded as follows: 0, absent; 1, mild-focal; 2, moderate-multifocal; 3, severe-diffuse. Evaluation of myofiber disarray was performed in the left ventricle only. Disarray is common and normal in the right ventricle, owing to trabeculation, and also at the junctions between the free-walls and septum, within the dividing points of trabeculae, and around blood vessels. Assessment was made only on regions of longitudinally orientated myofibers. Fibrosis was classified as follows: interstitial, strands of connective tissue surrounding myocytes; replacement, confluent areas of fibrosis surrounding myocytes; perivascular, surrounding blood vessels; and subendocardial, fibrosis below and including the endocardium.

Statistical analysis: Echocardiographic study {#sec010}
---------------------------------------------

Data were assessed graphically for normality, which was tested using Shapiro-Wilk tests. Normally distributed data was represented mean (±standard deviation) and non-normally distributed data was represented median (range).

Categorical variables were compared between groups using Chi square/Fisher's Exact tests. Normally distributed continuous variables were tested between the three groups using a one-way ANOVA, with pairwise comparisons using an independent samples t test. Non-normally distributed continuous variables were compared using a Kruskal-Wallis test, with pairwise comparisons using a Mann-Whitney U test. Significance was set at 5% with Bonferroni correction of p values for multiple comparisons.

To assess for a treatment effect, echocardiographic variables were compared before and after treatment with either pasireotide or hypophysectomy, using a Wilcoxon signed-rank test.

Statistical analysis: Histopathological study {#sec011}
---------------------------------------------

Histopathological variables were analysed to evaluate any significant differences between the three groups (controls, HCM and HS cats). Normality was assessed as before. Myocyte hypertrophy and myofibre disarray were converted to dichotomous variables (present/absent) for statistical analysis. These and other categorical variables were analysed using a Chi squared/Fisher's Exact test. Age, heart weight, heart weight: body weight ratio, RVFW, IVS and LVFW thickness were compared between groups using a Kruskal-Wallis test and body weight was compared using a one-way ANOVA. Post-hoc pairwise comparisons and Bonferroni adjustment were performed on significant results. P values \<0.05 were considered statistically significant overall.

Results {#sec012}
=======

Echocardiographic differences at enrolment {#sec013}
------------------------------------------

A total of 16 cats were enrolled in the control group, 24 cats in the DM group and 67 cats in the HS group. There was no significant difference in the baseline population characteristics of the three groups, other than HS cats being younger and heavier than cats in the other two groups ([Table 1](#pone.0194342.t001){ref-type="table"}). All cats of both sexes had been neutered years prior to study enrolment. Maximum LV wall thickness was significantly greater in cats with HS (6.5mm, 4.4--10.1mm) than DM (5.9mm, 4.2--9.1mm; p = 0.008) or healthy cats (5.2mm, 4.1--6.5mm; p\<0.001; [Fig 2](#pone.0194342.g002){ref-type="fig"}). Clinically significant LV hypertrophy (wall thickness ≥6mm) was present in 72% of the HS group, compared to 36% of diabetic cats and 21% of controls. Left atrial diameter was greater in the HS group (16.6mm, 13.0--29.5mm) than both cats with DM (15.2mm, 10.2--21.3mm; p = 0.001) and controls (14.0mm, 12.6--17.4mm; p\<0.001, [Fig 3](#pone.0194342.g003){ref-type="fig"}). Aortic insufficiency was more common in both HS and DM cats than in healthy controls (p\<0.001 and p = 0.018 respectively). A greater proportion of cats with HS exhibited reduced diastolic function (diastolic class pseudo-normal \[class 3\] or restrictive \[class 4\] in 27%) than did those in control (6%) or DM (13%) groups (p = 0.020). Despite these findings, cardiac biomarkers were not significantly different between groups (NTproBNP p = 0.213; cTnI p = 0.138). A summary of echocardiographic findings is presented in [Table 2](#pone.0194342.t002){ref-type="table"}.

![Box and whisker plot to illustrate the difference in maximum left ventricular (LV) wall thickness between the three groups of cats at enrolment.\
DM, diabetes mellitus; HS, hypersomatotropism.](pone.0194342.g002){#pone.0194342.g002}

![Box and whisker plots to illustrate the difference in left atrial size between groups at enrolment.\
DM, diabetes mellitus; HS, hypersomatotropism.](pone.0194342.g003){#pone.0194342.g003}

10.1371/journal.pone.0194342.t001

###### Population characteristics of cats enrolled in the echocardiographic study.

Normally distributed data are represented mean (±standard deviation) and compared using a one-way ANOVA. Non-normally distributed data are represented median (range) and compared using a Kruskal-Wallis test. Categorical variables are represented as percentages and compared using a Chi squared test.

![](pone.0194342.t001){#pone.0194342.t001g}

  Variable                                                           Healthy                                                    Diabetes mellitus                                       Hypersomatotropism                                                                                   P value
  ------------------------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ---------
  Number                                                             16                                                         24                                                      67                                                                                                   \-
  Age (years)                                                        12.4 (10.2--19.4) [^a^](#t001fn002){ref-type="table-fn"}   11.5 (5--17)                                            10.1 (5--15) [^a^](#t001fn002){ref-type="table-fn"}                                                  \<0.001
  Male (%)                                                           69%                                                        79%                                                     66%                                                                                                  0.301
  Pedigree (%)                                                       0%                                                         4%                                                      12%                                                                                                  0.381
  Body weight (kg)                                                   4.55 (2.68--6.46) [^a^](#t001fn002){ref-type="table-fn"}   4.48 (2.84--7.40) ^b^                                   5.70 (2.0--10.5) [^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn002){ref-type="table-fn"}     0.003
  Body condition score ≥6/9 [^Φ^](#t001fn003){ref-type="table-fn"}   28%                                                        37%                                                     24%                                                                                                  0.406
  **Clinical data**                                                                                                                                                                                                                                                                          
  Rectal temperature (°C)                                            38.1 (±0.3)                                                38.1 (±0.7)                                             38.0 (±0.6)                                                                                          0.651
  Respiratory rate (breaths per minute)                              36 (20--72)                                                32 (20--52)                                             32 (20--80)                                                                                          0.366
  Heart rate (beats/minute)                                          179 (±18)                                                  178 (±24)                                               172 (±24)                                                                                            0.290
  Systolic blood pressure (mmHg)                                     133 (120--169)                                             156 (105--171)                                          148 (120--171)                                                                                       0.870
  Murmur present (%)                                                 31%                                                        21%                                                     40%                                                                                                  0.956
  Gallop sound present (%)                                           0%                                                         8%                                                      6%                                                                                                   0.399
  Arrhythmia present (%)                                             0%                                                         4%                                                      3%                                                                                                   0.644
  **Laboratory data**                                                                                                                                                                                                                                                                        
  IGF-1 (ng/ml)                                                      396 (226--728) [^a^](#t001fn002){ref-type="table-fn"}      504 (171--749) [^b^](#t001fn002){ref-type="table-fn"}   1800 (1001-\>2000) [^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn002){ref-type="table-fn"}   \<0.001
  Insulin dose (IU per 24h)                                          .                                                          6 (3--8) [^a^](#t001fn002){ref-type="table-fn"}         16 (2--80) [^a^](#t001fn002){ref-type="table-fn"}                                                    \<0.001
  Fructosamine (μmol/L)                                              .                                                          453 (278--746)                                          525 (169--1,076)                                                                                     0.047
  NTproBNP (pmol/L)                                                  86 (24--1358)                                              50 (24--186)                                            74 (24--1219)                                                                                        0.213
  Cardiac troponin I (ng/ml)                                         0.02 (0--0.22)                                             0.04 (0.02--0.1)                                        0.03 (0.01--0.23)                                                                                    0.138

*IGF-1*, *insulin-like growth factor 1*;

^a/b^ indicates a statistically significant difference when pairwise comparison between these factors was performed

^Φ^ Laflamme D. Development and validation of a body condition score system for cats: a clinical tool. 1997 Feline Practice **25** 13 e18

10.1371/journal.pone.0194342.t002

###### Echocardiographic measurements of all cats enrolled in the study.

Normally distributed data are represented mean (±standard deviation) and compared using a one-way ANOVA. Non-normally distributed data are represented median (range) and compared using a Kruskal-Wallis test. Categorical variables are represented as percentages and compared using a Chi squared test.

![](pone.0194342.t002){#pone.0194342.t002g}

  Variable                                       Healthy                                                                                        Diabetes mellitus                                       Hypersomatotropism                                                                                P value
  ---------------------------------------------- ---------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------
  IVSd (mm)                                      4.9 (3.9--6.5) [^a^](#t002fn001){ref-type="table-fn"}                                          5.7 (4.2--9.1) [^b^](#t002fn001){ref-type="table-fn"}   6.5 (4.1--10.1) [^a^](#t002fn001){ref-type="table-fn"}^,^[^b^](#t002fn001){ref-type="table-fn"}   \<0.001
  LVFWd (mm)                                     4.6 (3.6--6.2) [^a^](#t002fn001){ref-type="table-fn"}                                          5.3 (3.8--7.3) [^b^](#t002fn001){ref-type="table-fn"}   5.9 (4.1--10.0) [^a^](#t002fn001){ref-type="table-fn"}^,^[^b^](#t002fn001){ref-type="table-fn"}   \<0.001
  Maximum LV thickness (mm)                      5.2 (4.1--6.5) [^a^](#t002fn001){ref-type="table-fn"}                                          5.9 (4.2--9.1) [^b^](#t002fn001){ref-type="table-fn"}   6.5 (4.4--10.1) [^a^](#t002fn001){ref-type="table-fn"}^,^[^b^](#t002fn001){ref-type="table-fn"}   \<0.001
  LVIDd (mm)                                     14.2 (11.2--17.6) [^a^](#t002fn001){ref-type="table-fn"}                                       15.4 (11.2--20.3)                                       16.1 (11.9--20.8) [^a^](#t002fn001){ref-type="table-fn"}                                          0.013
  LV FS (%)                                      51 (±7.6)                                                                                      45 (±7.8)                                               46 (±3.4)                                                                                         0.351
  LA diameter (mm)                               14.0 (12.6--17.4) [^a^](#t002fn001){ref-type="table-fn"}                                       15.2 (10.1--21.3)                                       16.6 (13.0--29.5)[^a^](#t002fn001){ref-type="table-fn"}                                           \<0.001
  LA:Ao ratio                                    1.3 (1.0--2.2) [^a^](#t002fn001){ref-type="table-fn"}                                          1.3 (1.0--2.0)                                          1.6 (1.0--2.9) [^a^](#t002fn001){ref-type="table-fn"}                                             \<0.001
  LA FS (%)                                      31 (20--50)                                                                                    30 (14--47)                                             29 (1--63)                                                                                        0.570
  LA appendage flow velocity (msec^-1^)          0.47 (±0.15)                                                                                   0.41 (±0.12)                                            0.42 (±0.42)                                                                                      0.736
  LVOT velocity (msec^-1^)                       1.0 (±0.3)                                                                                     0.94 (±0.2) [^a^](#t002fn001){ref-type="table-fn"}      1.2 (±0.3) [^a^](#t002fn001){ref-type="table-fn"}                                                 0.008
  RVOT velocity (msec^-1^)                       0.9 (±0.3)                                                                                     1.0 (±0.4)                                              0.9 (±0.2)                                                                                        0.911
  Mitral E velocity (msec^-1^)                   0.7 (±0.12)                                                                                    0.7 (±0.19)                                             0.8 (±0.17)                                                                                       0.275
  E deceleration time (ms)                       77 (±18)                                                                                       74 (±13)                                                74 (±23)                                                                                          0.758
  Mitral A velocity (msec^-1^)                   0.6 (±0.17)                                                                                    0.6 (±0.12)                                             0.6 (±0.18)                                                                                       0.450
  Mitral E:A ratio                               1.2 (0.7--1.9)                                                                                 1.2 (0.8--2.0)                                          1.2 (0.8--4.8)                                                                                    0.296
  Diastolic class ≥3                             6% [^a^](#t002fn001){ref-type="table-fn"}                                                      13%                                                     27% ^a^                                                                                           0.020
  TDI S's velocity (msec^-1^)                    0.10 (±0.03)                                                                                   0.09 (±0.02)                                            0.09 (±0.03)                                                                                      0.297
  TDI E's velocity (msec^-1^)                    0.09 (±0.02) [^a^](#t002fn001){ref-type="table-fn"}^,^[^b^](#t002fn001){ref-type="table-fn"}   0.06 (±0.02) [^a^](#t002fn001){ref-type="table-fn"}     0.07 (±0.02) [^b^](#t002fn001){ref-type="table-fn"}                                               0.004
  TDI A's velocity (msec^-1^)                    0.07 (±0.03)                                                                                   0.09 (±0.03)                                            0.08 (±0.03)                                                                                      0.476
  Mitral E: TDI E' ratio                         9.0 (±1.7)                                                                                     10.6 (±2.5)                                             12.3 (±4.3)                                                                                       0.027
  Aortic insufficiency (%)                       0% [^a^](#t002fn001){ref-type="table-fn"}^,b^                                                  17% [^a^](#t002fn001){ref-type="table-fn"}              31% ^b^                                                                                           0.006
  Systolic anterior motion of the mitral valve   12%                                                                                            4%                                                      9%                                                                                                0.592

^a/b^ indicates a statistically significant difference when pairwise comparison between these factors was performed

Changes in echocardiographic variables after treatment of hypersomatotropism {#sec014}
----------------------------------------------------------------------------

In the HS group, clinical and echocardiographic data were available at a minimum of 6 months after treatment for 9 cats that received long-acting pasireotide medical treatment (PAS group) and 20 cats that underwent surgical hypophysectomy (HYP group). There were no statistically significant differences between these groups at baseline. Median follow-up time for treated cats was 6 months (range 6--24 months) in the HYP group and 12 months (range 6--24 months) in the PAS group. A statistically significant reduction in all measures of diastolic LV wall thickness and LA size was present in the HYP group, whereas only reduction in LA diameter was present in the PAS cats ([Table 3](#pone.0194342.t003){ref-type="table"}). Prior to treatment, 65% of cats in the hypophysectomy group had clinically significant LV hypertrophy (≥6mm); after treatment, this reduced to 15%. There was no change in the proportion of cats affected by aortic insufficiency after either treatment, but HYP cats showed an improvement in diastolic function, with fewer cats having pseudonormal or restrictive function (p = 0.013).

10.1371/journal.pone.0194342.t003

###### Echocardiographic and plasma IGF-1 measurements before and after treatment of acromegaly.

![](pone.0194342.t003){#pone.0194342.t003g}

  Echocardiographic parameter         Pre-treatment       Post-treatment      P value
  ----------------------------------- ------------------- ------------------- -----------------------------------------------
  **Hypophysectomy group (n = 20)**                                           
  IVSd (mm)                           5.9 (4.4--8.1)      4.9 (3.6--6.6)      \<0.001 [\*](#t003fn001){ref-type="table-fn"}
  LVFWd (mm)                          5.5 (4.2--8.9)      4.9 (3.7--8.4)      0.001 [\*](#t003fn001){ref-type="table-fn"}
  LVmax (mm)                          6.1 (4.4--8.9)      5.2 (3.9--8.4)      0.002 [\*](#t003fn001){ref-type="table-fn"}
  LA diameter (mm)                    16.3 (13.0--21.0)   14 (11.5--16.6)     0.001 [\*](#t003fn001){ref-type="table-fn"}
  LVIDd (mm)                          16.8 (11.9--19.2)   15.1 (10.2--19.4)   0.01 [\*](#t003fn001){ref-type="table-fn"}
  LV FS (%)                           43 (20--69)         51 (36--74)         0.117
  LA FS (%)                           28 (15--57)         31 (18--58)         0.627
  IGF-1 (ng/mL)                       1961 (1055--2000)   85 (15--721)        0.008 [\*](#t003fn001){ref-type="table-fn"}
  **Pasireotide group (n = 9)**                                               
  IVSd (mm)                           6.7 (5.5--8.0)      6.1 (4.8--8.0)      0.575
  LVFWd (mm)                          6.2 (5.8--8.2)      5.8 (4.4--7.5)      0.208
  LVmax (mm)                          6.7 (5.9--8.2)      6.1 (5--8)          0.575
  LA diameter (mm)                    17.4 (14.1--22.4)   15.6 (11.8--19.3)   0.028 [\*](#t003fn001){ref-type="table-fn"}
  LVIDd (mm)                          15.5 (12.6--17.7)   15.9 (11.3--17.9)   1.000
  LV FS (%)                           45 (41--60)         47 (29--51)         0.161
  LA FS (%)                           34 (27--60)         31 (22--42)         0.465
  IGF-1 (ng/mL)                       2000 (993--2000)    1659 (18--2000)     0.080

\*indicates statistical significance at the 5% level

Evaluation of myocardial tissue samples {#sec015}
---------------------------------------

Twenty-one cats suitable for inclusion in the HS group were selected; therefore 21 cases were also selected for each of the HCM and control groups. Pituitary histopathology was available for review in 16/21 cats with acromegaly. Findings were consistent with acidophil adenoma in 11 (69%) and acidophil hyperplasia in 5 (31%). Of the remaining cases where tissue was not available for review, reports were all consistent with either of these diagnoses. None of the 21 cats in the HS group had tissue findings consistent with acidophil carcinoma. Population characteristics and gross pathology findings of all cats are shown in [Table 4](#pone.0194342.t004){ref-type="table"}. Absolute heart weight was significantly greater in cats with HCM (p\<0.001) and cats with HS (p = 0.004) than the control group. There was no significant difference in relative heart weight between groups. There was no significant difference in ventricular wall thickness between groups following pairwise comparisons with Bonferroni correction for IVS and LVFW thickness measurements.

10.1371/journal.pone.0194342.t004

###### Population characteristics of cats whose myocardial tissue was analysed in the histopathologic study.

*HCM*, *hypertrophic cardiomyopathy; HW*, *heart weight; BW*, *body weight; RVFW*, *right ventricular free wall thickness; IVS*, *interventricular septal thickness; LVFW*, *left ventricular wall thickness*.

![](pone.0194342.t004){#pone.0194342.t004g}

                              Control                                                                                             HCM                                                        Hypersomatotropism                                         p-value
  --------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------
  Number                      21                                                                                                  21                                                         21                                                         \-
  Male (%)                    38                                                                                                  71                                                         57                                                         0.080
  Pedigree (%)                43                                                                                                  14                                                         10                                                         0.030
  Age (years)                 4.0 (2.0--10.0) [^a^](#t004fn001){ref-type="table-fn"}^,^[^b^](#t004fn001){ref-type="table-fn"}     8.0 (3.0--15.0) [^a^](#t004fn001){ref-type="table-fn"}     10.8 (3.1--14.6) [^b^](#t004fn001){ref-type="table-fn"}    \<0.001
  Body weight (kg)            4.2 (2.0--8.0)                                                                                      4.9 (3.9--7.0)                                             5.4 (3.1--8.3)                                             0.024
  Absolute heart weight (g)   15.5 (10.8--32.6) [^a^](#t004fn001){ref-type="table-fn"}^,^[^b^](#t004fn001){ref-type="table-fn"}   27.4 (18.0--58.0) [^a^](#t004fn001){ref-type="table-fn"}   25.0 (19.7--37.6) [^b^](#t004fn001){ref-type="table-fn"}   \<0.001
  HW: BW (%)                  0.39 (0.29--0.68)                                                                                   0.63 (0.26--1.4)                                           0.47 (0.38--0.60)                                          0.160
  RVFW (mm)                   1.9 (0.9--2.9)                                                                                      2.5 (1.0--4.0)                                             2.0 (1.0--5.0)                                             0.096
  IVS (mm)                    7.0 (3.0--9.0)                                                                                      9.5 (4.0--12.0)                                            8.0 (4.0--12.0)                                            0.032
  LVFW (mm)                   8.0 (3.0--12.0)                                                                                     10.0 (3.0--18.0)                                           8.0 (4.0--12.0)                                            0.024

^a/b^ indicates a statistically significant difference when pairwise comparison between these factors was performed

Myocyte hypertrophy was present in all 63 cats reviewed. In the control group, no cat had severe myocyte hypertrophy, whereas severe hypertrophy was detected in some cats of both the HCM and HS groups ([Fig 4](#pone.0194342.g004){ref-type="fig"}). There was no significant difference between the groups in quantitative scores for perivascular fibrosis (p = 0.249), subendocardial fibrosis (p = 0.092), replacement fibrosis (p = 0.672) or intramural arteriosclerosis (p = 0.364). Interstitial fibrosis was more frequent in the HS group than the control group (p\<0.001). There was no significant difference in interstitial fibrosis between the HS and HCM (p = 0.343) or HCM and control (p = 0.052) groups. Myofiber disarray was more frequently observed in the HCM group than the HS (p\<0.001) or control (p = 0.002) groups, and in the control group than the HS group (p = 0.016). There was a significant difference in inflammatory cell infiltration (p = 0.017, [Fig 5](#pone.0194342.g005){ref-type="fig"}) and myocyte degeneration (0.037) between groups, however no significant difference remained following pair-wise analysis.

![Box plot to show the proportion of cats in each group affected by different grades of (top) myocyte hypertrophy and (bottom) myocyte disarray.\
No cats reviewed were classified as non-hypertrophic.](pone.0194342.g004){#pone.0194342.g004}

![Box plot to show the proportion of cats affected by myocardial inflammatory cell infiltrate in each group.](pone.0194342.g005){#pone.0194342.g005}

Discussion {#sec016}
==========

These data strongly suggest that hypersomatotropism in cats is associated with left ventricular hypertrophy, which is largely reversible following hypophysectomy. The clinical, echocardiographic and histopathological findings described in this study closely mimic those detected in humans with acromegalic cardiomyopathy. Therefore, we propose that feline acromegalic cardiomyopathy represents an attractive spontaneously occurring model of the human disease, and its study could bridge the gap between engineered rodent models and the human condition. The relatively high prevalence of the disease in the cat, compared to humans, further offers an attractive characteristic for its future study.

This is the first study to deliver a detailed description of feline acromegalic cardiomyopathy and to offer comparison with non-acromagelic diabetic and apparently healthy control cats. Feline acromegalic cardiomyopathy is characterised *ante mortem* by echocardiographic evidence of LV hypertrophy and diastolic dysfunction together with an increased prevalence of aortic insufficiency and left atrial dilation (presumably secondary to LV diastolic dysfunction and volume loading effects of diabetes) compared to control cats. These findings support those reported in previous case series \[[@pone.0194342.ref028], [@pone.0194342.ref037]\], but this time on the basis of rigorous comparison of cats with acromegaly to a suitable population of controls.

It is interesting to note the relatively limited reverse myocardial remodelling of cats treated with pasireotide compared to hypophysectomy. This might be explained by the fact that IGF-1 did not reduce significantly in those cats treated medically, in contrast to hypophysectomy-treated cats. In one recent case series, a statistically significant reduction in IGF-1 was reported after treatment with pasireotide, but the magnitude of change reported was much lower than for the cats undergoing hypophysectomy in this study \[[@pone.0194342.ref046]\]. Without further study in a larger cohort of cats using a treat-to-target protocol, it is impossible to say whether or not long-term medical management of acromegalic cardiomyopathy with somatostatin receptor agonists is inferior to surgical treatment. Interestingly, both medical and surgical treatment of HS in humans is associated with a reduction in LV mass \[[@pone.0194342.ref024]\]. In humans, older patients with a longer duration of HS have more severe cardiac dysfunction and a less profound treatment response than younger patients \[[@pone.0194342.ref016], [@pone.0194342.ref053]--[@pone.0194342.ref064]\]. These older patients are also more likely to be diabetic \[[@pone.0194342.ref065]\]. Our population of cats, all of whom were diabetic, may represent a longer duration of disease and therefore the response to medical treatment may be less profound than seen in most humans with acromegaly. The dose used in this study may have been inadequate, or a species difference in response to somatostatin analogs between cats and humans is possible.

Similarities between the cardiac phenotype in cats with HS and human acromegalic cardiomyopathy were also observed at the tissue level. In humans, myocyte hypertrophy was present in 93% patients (100% cats), interstitial fibrosis in 85% (\>90% cats), intramural arteriosclerosis in 22% (approximately 50% cats) and inflammatory cell infiltrates in 59% (approximately 40% cats). Similarly to cats, myocyte disarray is uncommon \[[@pone.0194342.ref025]\]. In humans, reversal of histopathological abnormalities has been observed after treatment with octreotide \[[@pone.0194342.ref064]\]. It was not possible to obtain myocardial samples post-hypophysectomy in this study due to excellent long-term survival rates. Myocardial biopsy is not routinely performed in cats, so assessment of myocardial changes pre- and post-treatment in the same cats was impossible.

Evidence of myocardial hypertrophy was common in all groups of cats studied, both echocardiographically and histopathologically. Clinically significant LV hypertrophy (\>6mm) was identified in 21% of control cats using echocardiography and histopathological evidence of myocyte hypertrophy was present in 100% of control cats at post-mortem. Echocardiographic prevalence of HCM has been reported at 29.4% in a population of apparently healthy cats \>9 years old \[[@pone.0194342.ref040]\], and one recent histopathological study \[[@pone.0194342.ref066]\] found that quantitative measures of myofiber diameter were not significantly different between hearts from cats with HCM and controls, even though myocyte hypertrophy is considered one of the principal changes in feline HCM \[[@pone.0194342.ref001]--[@pone.0194342.ref004]\]. There is no published reference for feline myocyte size, and therefore many studies (including this one) use a semiquantitative scoring system. The main problem with using such a system is that there is little room to account for normal biologic variation. It is possible that the "mild-focal" hypertrophy reported in the control group represented a normal variant in older cats. Clearly, a more robust reference for myocyte size is required in cats to facilitate greater accuracy in future research.

As expected, myofiber disarray---considered the histopathologic gold standard for diagnosis of HCM \[[@pone.0194342.ref002], [@pone.0194342.ref067], [@pone.0194342.ref068]\]---was more frequently observed in the HCM group than the HS or control groups. Myofiber disarray was also found more frequently in the control group than the HS group. This is most likely explained by a random difference in prevalence of HCM between groups, as both groups may have included cats with concurrent (incidental) HCM.

Interstitial fibrosis was more frequent in the HS group than the control group, but not the HCM group. Interstitial fibrosis is considered a characteristic histopathological finding in HCM in both humans and cats \[[@pone.0194342.ref001]\], and has also been described in both human \[[@pone.0194342.ref025]\] and feline \[[@pone.0194342.ref028]\] patients with acromegaly. Increased collagen turnover has also been demonstrated both in the cat \[[@pone.0194342.ref069]\] and human \[[@pone.0194342.ref070]\] with acromegaly. One previous study in humans found that myocardial fibrosis increases with age \[[@pone.0194342.ref071]\], so the presence of fibrosis in itself may not always indicate disease. Despite attempting to age-match the groups in our histopathological study, cats in the control group were significantly younger than in the HS and HCM groups. Therefore, it remains possible that interstitial fibrosis was related to age rather than disease. There was no significant difference between groups in the degree of replacement fibrosis or intramural arteriosclerosis. The latter has previously been reported in association with feline HS \[[@pone.0194342.ref028]\], but it is often also included as a diagnostic criterion for HCM \[[@pone.0194342.ref072]\]. Once again, the prevalence of incidental cardiomyopathy in geriatric cats may explain the lack of significant differences between groups.

A crucial difference between humans and cats with acromegalic cardiomyopathy is the proportion of individuals affected by DM. All cats with acromegaly in our study had DM, and only four cases of non-diabetic acromegalic cats have been reported in the literature thus far \[[@pone.0194342.ref032]--[@pone.0194342.ref033]\]. In contrast, DM is only reported in 15--35% of humans with HS \[[@pone.0194342.ref065], [@pone.0194342.ref073]\]. Because of this, determining which myocardial changes are caused by the diabetic state and which directly relate to over-secretion of GH and IGF-1 is a challenge in cats. In this study, the non-acromegalic diabetic state (DM group) did not appear to be associated with clinically significant myocardial hypertrophy. However, the group size was relatively small and a subtle effect of diabetes may not have been detected. Previously, diabetic cats have been reported to exhibit a progressive diastolic dysfunction, but LV hypertrophy was not identified in these cats \[[@pone.0194342.ref019]\]. Additionally, in the present study, histopathology on non-acromegalic diabetic cats was not included in the statistical analysis due to lack of suitable material. Despite this, our data suggests that the GH and IGF-1 excess of acromegaly has significant effects on the myocardium over and above any changes induced by diabetes alone. Despite the relatively rapid reversal of these changes when the acromegaly was treated effectively through surgery, we cannot be entirely certain from this study that DM itself was not the cause of the reversible changes. We would recommend that a larger cohort of diabetic cats is studied, with suitable control population for comparison, before the possibility of a diabetic cardiomyopathy in cats is excluded. What we can say from this data is that the feline acromegalic cardiomyopathy, albeit one associated with concurrent diabetes in this population, was largely reversible with treatment by hypophysectomy, excluding the possibility that hypertrophy in the HS group was caused by primary myocardial disease.

In summary, this report describes in detail the cardiac manifestations of spontaneously occurring feline hypersomatotropism at the clinical and histopathological level. Many phenotypic similarities with human acromegalic cardiomyopathy were identified. Furthermore, we have refined the phenotype of this model by comparing cats with acromegaly cats to those with potential confounding diseases, such as HCM and diabetes. We therefore suggest that feline acromegalic cardiomyopathy represents an appealing, naturally occurring model to study, with significant potential to form the foundations of future research. Study of privately-owned pet cats with acromegaly is a realistic option, if owners consent to enrolment of their cat in clinical trials; a research opportunity in a shared environment, with higher disease prevalence, a shorter lifespan and a higher event-rate than humans. Research centred on the naturally-occurring feline disease could facilitate identification of novel therapeutics that may be rapidly translated into the human clinic. Furthermore, the easier acquisition of suitable myocardial tissue from cats (given their shorter lifespan) compared to human patients will facilitate exploration of the cellular pathways which trigger ventricular remodelling; this may allow the development of anti-hypertrophic therapies potentially relevant to other triggers for hypertrophy.
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